IPO - Aileron Therapeutics, Inc.

Form Type: S-3

Filing Date: 2025-05-16

Corporate Action: Ipo

Type: New

Accession Number: 000119312525121358

Filing Summary: Rein Therapeutics, Inc. filed this S-3 registration statement for a proposed public offering of securities with an aggregate initial offering price of up to $150,000,000. The filing includes two prospectuses: a base prospectus for general securities issuance including debt securities, common stock, preferred stock, warrants, and units, and a sales agreement prospectus related to the specific issuance of up to $15,773,673 of common stock under a sales agreement with H.C. Wainwright & Co., LLC. The document outlines Rein Therapeutics’ position as a clinical stage biopharmaceutical company focused on developing treatments for orphan pulmonary and fibrosis indications, detailing their lead product candidates, LTI-03 and LTI-01, along with their recent acquisition of Lung Therapeutics, Inc. This document serves as an essential component for potential investors, providing insights on risks associated with investment, the offering process, and corporate strategies.